Barr Says Citizen Petition Is Remaining Obstacle To DDAVP Generic Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal court ruling that Sanofi-Aventis patents on desmopressin tablets are invalid and not infringed "effectively ends" 30-month stay of approval on Barr's ANDA for the bed-wetting therapy, generic firm says. A pending citizen petition seeks to establish specific bioequivalence requirements for DDAVP generics.
You may also be interested in...
Barr Launches DDAVP Generic With 180-Day Exclusivity
FDA approves Barr’s ANDA for Sanofi-Aventis’ bed-wetting therapy DDAVP. Approval comes five months after Barr prevailed in a patent dispute with DDAVP manufacturer Ferring.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter